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Executive Summary 
Hospice has been shown to improve quality of life for terminally ill patients and their 
families by addressing pain and symptom management, and providing emotional and 
spiritual support (MA Expert Panel on End-of-Life Care, 2010). Hospice is administered 
as an optional benefit under a Medicaid state plan for beneficiaries who are certified by a 
physician to be terminally ill with a life expectancy of six months or less and who forego 
curative treatment. The benefit covers the palliation and management of terminal illness, 
inclusive of all related care, medication and supplies, counseling, and room and board in 
nursing facilities.1
 
 
MassHealth, the Massachusetts (MA) Medicaid program, administers a hospice benefit 
for eligible Fee-for-Service (FFS) plan members. MassHealth began offering a FFS 
hospice benefit in 1988. During State Fiscal Years (FY) 2006-2008 (July 1, 2005-June 
30, 2008), the MassHealth hospice program experienced increased utilization and 
expenditures. To better understand this growth and its effect on services and customer 
satisfaction, MassHealth requested that the Center for Health Policy & Research 
(CHPR), at the University of Massachusetts Medical School’s (UMMS) Commonwealth 
Medicine Division, conduct a study pertaining solely to its FFS hospice benefit. 
 
The MassHealth Hospice Program: Overview and Analysis study (the Hospice study) 
employed mixed methods to conduct a descriptive analysis of primary and secondary 
data, using document review, key informant interviews, and MassHealth claims and 
enrollment data. The study encompassed four phases, and each phase concluded with a 
detailed report. Phase 1 explained the structure and implementation of the MassHealth 
hospice benefit. Phase 2 examined the increase in MassHealth hospice benefit 
utilization and expenditures. Phase 3 assessed MassHealth member and family 
satisfaction with the benefit. Phase 4 described the end of life (EOL) services related to 
a terminal illness, including hospice, provided by Medicaid programs in five selected 
states. This final report synthesizes and summarizes the study’s four phases. 
Key Findings 
• Access, Eligibility, and Election
                                               
1 Commonwealth of Massachusetts MassHealth Provider Manual Series, Hospice Manual, pp. 4-
9  through 4-11, and 4-8 (130 CMR 437.423 and 130 CMR 437.421(D)(5)) 
: The FFS hospice benefit is available to eligible 
MassHealth members, except those in the Basic, Essential and Limited coverage 
plans. Adults, age 21 and older, who elect the benefit, are required to forego curative 
treatment. Key informants report that members’ delay in hospice election or their 
refusal of the benefit may impact their length of stay in hospice, their EOL care or 
both. 
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• Reimbursement
• 
: For members with only Medicaid coverage (MH-only), MassHealth 
pays the hospice provider on a per diem basis according to the level of care 
provided, as well as for room and board (R&B) when the member resides in a skilled 
nursing facility (SNF). When members covered by both Medicare and Medicaid (dual 
eligible) elect hospice, MassHealth pays only for R&B in a SNF, while Medicare pays 
for all other hospice services regardless of where the member resides. Hospice 
providers are responsible for billing MassHealth and passing R&B payments to 
SNFs. This is known as the “pass-through” system. According to federal regulations, 
hospice R&B must be equal to at least 95% of what the state would pay a SNF for a 
non-hospice beneficiary. MassHealth reimburses 95% of the SNF R&B rate. In some 
cases, hospice providers contract with SNFs to pay the full R&B charge, absorbing 
the 5% rate difference. 
Utilization and Expenditures
• 
: During the period FY 2006-2008, the number of MH-
only hospice beneficiaries remained virtually constant, averaging 620 annually, and 
approximately three-fourths had a length of stay (LOS) of three weeks or less. 
Simultaneously, the number of dual eligible hospice beneficiaries rose 68%, from 
3,849 in FY 2006 to 5,702 in FY2008. More than 60% of these dual eligibles had an 
average LOS of at least four weeks. The number of dual eligibles with a LOS of more 
than 6 months rose 81%, from 587 in FY 2006 to 1066 in FY 2008. MassHealth 
hospice expenditures rose 78%, from $58.9 million in FY 2006 to $105.0 million in 
FY 2008, with the largest expenditure category being R&B payments for dual 
eligibles, comprising 90% of all hospice expenditures in each study year. 
Beneficiary and Family Satisfaction
• 
: Family members of hospice decedents who 
participated in the study described the MassHealth hospice benefit as ‘5’ (excellent) 
on a scale of 1 to 5. They stated that hospice “more than met” patients’ needs for 
pain and symptom management as well as for assistance with activities of daily 
living. They also reported that hospice met the emotional and spiritual needs of both 
patients and family members. 
Other States
Conclusions 
: An examination of the Medicaid hospice benefit in five other states 
showed variation in the populations eligible for hospice, coverage models, and R&B 
reimbursement. Palliative care was provided on an ad-hoc basis for Medicaid 
beneficiaries who were either ineligible for, did not have access to, or did not elect 
hospice. 
While hospice can improve quality of life for terminally ill patients with a prognosis of 6 
months or less to live, the study found that patient and provider knowledge of EOL 
services, their preferences for EOL care, as well as federally-defined eligibility 
requirements, impact MassHealth members’ use of the hospice benefit. Those 
interviewed see these challenges to electing the benefit as missed opportunities for both 
MassHealth beneficiaries and their families. 
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Hospice providers report administrative and financial challenges when acting as the 
intermediary between MassHealth and SNFs for R&B reimbursement. Further, over 90% 
of the annual MassHealth hospice budget pays for the R&B expenses of hospice 
beneficiaries in SNFs who are dually eligible for Medicare. This fiscal reality 
overshadows the relatively small annual expenditures for patient care and family support 
the MassHealth hospice benefit provides. 
 
MassHealth and the other state Medicaid programs studied currently do not offer a 
palliative care benefit for their members with a terminal illness who are not eligible for 
hospice. By covering a range of services that includes curative treatment and palliative 
care, as well as hospice, states can increase access to high quality EOL care for these 
members and their families. 
Recommendations 
The following recommendations from this study suggest opportunities for MassHealth to 
provide a continuum of care in a cost efficient manner, from the time of terminal 
diagnosis through the end of life and during bereavement, for all MassHealth members 
with serious chronic and terminal illness. 
• Conduct further claims analyses to determine and compare utilization and 
expenditures for EOL services provided to MassHealth decedents without access to 
the hospice benefit, those who were eligible but had short hospice LOS, and those 
who did not elect the benefit. Results can advise the feasibility of extending the 
hospice benefit, for example, to terminally ill members in the Basic, Essential and 
Limited coverage plans, which do not include hospice. 
• Examine the hospice R&B pass-through reimbursement system, the “95% rule” for 
reimbursing hospice R&B, and R&B expenditures isolated from payments for hospice 
care.  
• Consider further analyses of quantitative and qualitative data to better understand 
utilization and cost of EOL care related to a terminal illness, including hospice, for 
MH-only and dually eligible beneficiaries. 
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1 Introduction 
Hospice is an optional benefit under a Medicaid state plan for beneficiaries who are 
certified by a physician to be terminally ill with a life expectancy of six months or less and 
who forego curative treatment. The benefit covers palliation of the terminal illness, 
inclusive of all care, medication, supplies, counseling, and room and board in a nursing 
facility for the member, and support for the member’s family. 
MassHealth has administered a Fee-for-Service (FFS) hospice benefit under the 
Massachusetts (MA) Medicaid state plan since 1988. During State Fiscal Years 2006-
2008 (July 1, 2005-June 30, 2008), the MassHealth hospice benefit experienced 
increased utilization and expenditures. To better understand this growth, the MassHealth 
Long Term Services and Support Unit requested the Center for Health Policy and 
Research (CHPR), in the University of Massachusetts Medical School’s (UMMS) 
Commonwealth Medicine Division, to conduct a multi-phase study of its FFS hospice 
benefit. As a program evaluation project, the study was exempt from the UMMS 
Institutional Review Board process. 
The MassHealth Hospice Program: Overview and Analysis study comprises four phases. 
Each phase produced a detailed report addressing the following aims: 
• Phase 1: Described how the hospice benefit is currently structured and 
implemented (Lang, Posner, & Anderson, 2011) 
• Phase 2: Examined utilization and expenditures of the hospice benefit during 
State Fiscal Years (FY) 2006, 2007, and 2008 (Bhang & Zhang, 2010) 
• Phase 3 : Assessed beneficiary and family member satisfaction with the hospice 
benefit (Lang & Posner, 2011) 
• Phase 4: Identified alternative models for hospice and other services for 
terminally ill Medicaid beneficiaries that exist in other states (Lang & Posner, 
2012) 
This Final Report provides a brief background section and then summarizes the 
methods and key findings from Phases 1 through 4, and offers recommendations for 
MassHealth’s consideration. 
2 Background 
2.1 Access/Election of Hospice 
Studies indicate that hospice provides high quality care at the end of life (EOL) and 
elicits excellent patient and family satisfaction ratings (Rickerson, Harrold, Kapo, Carroll, 
& Casarett, 2005). However, Medicaid patients historically either lack access to needed 
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EOL care, or may delay or refuse hospice care for several reasons: lack of direct 
knowledge of hospice, cultural beliefs around death and dying, or a reluctance to accept 
a terminal prognosis and stop curative treatments (Head et al., 2010). 
2.2 Hospice Utilization and Expenditures 
The literature suggests that terminally ill patients and their families benefit most from 
hospice care with a length of stay (LOS) of at least 60 days (MA Expert Panel on End-of-
Life Care, 2010). Yet, nationally, the median hospice LOS remained steady at three 
weeks from 2006-2008 (The National Hospice and Palliative Care Organization, 2010). 
In 2008, over one-third of hospice patients either died, or elected curative or emergency 
treatment within seven days of enrollment in hospice and were thus discharged 
(NHPCO, 2010). With very short stays, there is inadequate time for providers to assess 
patient and family needs and implement effective hospice services. Thus, patients and 
their families may benefit from earlier enrollment in hospice leading to longer lengths of 
hospice stay (Casarett, 2011; Medpac, 2011; Rickerson et al., 2005).   
Over the last decade, more terminally ill patients have elected hospice and stayed 
longer. The National Hospice and Palliative Care Organization (NHPCO) reports that 
from 2000-2009, the number of Medicare hospice beneficiaries in the U.S rose 19% to 
1.1 million.2
NHPCO also reports that the majority of Medicaid hospice beneficiaries are dually 
eligible for Medicare. For dually eligible beneficiaries, Medicare pays for hospice care, 
and for those who reside in a skilled nursing facility (SNF), the state Medicaid program 
pays only for room and board (R&B). State hospice budgets can be misleading to 
policymakers because Medicaid hospice expenditures in large part cover SNF R&B “that 
the state otherwise would have been paying directly to the SNF...if hospice had not been 
involved”. Thus, it is important to consider the cost of Medicaid hospice care aside from 
the residential cost (NHPCO, 2011). 
 With greater hospice use, Medicare hospice expenditures more than tripled. 
In the same 10 year period, the average LOS at the 90th percentile rose from 141 to 237 
days (very long stays). Increases in very long LOS for Medicare hospice beneficiaries 
account for the significant rise in hospice expenditures (Medpac, 2011). 
2.3 Benefits of Palliative Care 
Palliative care focuses on “relieving suffering and achieving the best possible quality of 
life” for both patients with a life-threatening illness, and their family members (Head et 
al., 2010; Kelley & Meier, 2010). Palliative care can be provided along with curative 
treatment prior to election of hospice (Lang & Posner, 2012). Studies have shown that 
incorporating palliative care early in the progression of the disease provides better 
quality of care, and supports the transition to hospice when curative treatment is neither 
effective nor desired (Greer et al., 2011; Meier, Tuch, Campbell, Keyserling, & Morrison, 
2009; Rickerson et al., 2005). The American Society of Clinical Oncology, in its February 
                                               
2 According to NHPCO, Medicare covered over 84% of hospice patients nationally in 2008. 
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2012 Provisional Clinical Opinion, states, “…combined standard oncology care and 
palliative care should be considered early in the course of illness for any patient with 
metastatic cancer and/or high symptom burden” (Smith et al., 2012). 
While improving quality of life, hospice may also lower the cost of EOL care. Palliative 
care programs, including hospice, provide case management and care at costs lower 
than those associated with acute care services for patients at the end of life who do not 
access hospice (Head et al., 2010; NHPCO, 2010). As state Medicaid authorities 
implement initiatives to improve EOL care and reduce costs, they may consider payment 
models other than the FFS system (Meier et al., 2009). 
2.4 Expert Panel on End-of-Life Care 
The Massachusetts Expert Panel on End-of-Life Care (the Expert Panel) was 
established by the state legislature and convened in 2009 to study the Commonwealth’s 
health care delivery for patients with serious chronic conditions, and to identify best 
practices and “any legislative, regulatory, or other policy changes necessary to 
implement its recommendations”. The Expert Panel’s October 2010 report (MA Expert 
Panel on End-of-Life Care, 2010) recommends that: 
• all health care organizations should provide access to palliative care and hospice 
services for patients with serious advancing illness, as demonstrated by passage 
of the New York State Palliative Care Information Act (Ibid, pg. 20); and 
• all health plans should provide hospice coverage, referring specifically to the 
three MassHealth plans that currently exclude it - MassHealth Basic, Limited, and 
Essential (Ibid, pg. 23) 
3 Methods 
CHPR collaborated with MassHealth in determining the methods used for each of the 
four study phases. As Table 1 summarizes, CHPR used primarily qualitative methods in 
Phases 1, 3, and 4, and quantitative methods in Phase 2. 
Phase 2, conducted first, used MassHealth enrollment (MA-21) and claims (MMIS3
 
) data 
for the three year period FY 2006-2008. Data for this period were both complete and 
current in 2009. The study population was defined as all MassHealth members who had 
at least one paid FFS hospice claim, and was divided into three subgroups: MassHealth 
only (MH-only) members (those with no other health insurance); dual-eligibles 
(MassHealth members also enrolled in Medicare); and those with MassHealth and  
                                               
3 MMIS = Medicaid Management Information System 
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Table 1. Summary of Methodologies Employed in the MassHealth (MH) Hospice 
Program: Overview and Analysis Study 
 Phase 1 Phase 2 Phase 3 Phase 4 
Approach Qualitative Quantitative Qualitative Qualitative 
Data 
Sources  
Federal and state 
legislative, 
regulatory, policy, 
and program 
documents  
Eleven (11) key 
informant face-to-
face and phone 
interviews, 
conducted between 
March 12-June 16, 
2010 
Published reports 
MH MMIS hospice 
claims and MA 21 
member 
enrollment data, 
pulled February-
November 2008 
MH MMIS hospice 
claims and member 
enrollment data, 
pulled December 
2010  
 
Nine (9) key 
informant phone 
interviews, 
conducted between 
June 20-July 28,  
2011 
Nine (9) key 
informant phone 
interviews, 
conducted 
between January 
18-April 27, 2011 
Sample  Hospice providers 
Hospice/EOL care 
provider 
associations  
Federal and state 
government  
Subject matter 
experts 
MH-only, dual 
eligible, and 3rd 
party members 
with ≥1 paid 
hospice claims in  
FY2006-2008 
Family members of 
MH hospice 
beneficiaries who 
died during 
CY2008-2009 
Medicaid and the 
Hospice 
Association in five 
selected states: 
Arizona (AZ) 
Florida (FL) 
New Hampshire 
(NH) 
New York (NY) 
Oklahoma (OK) 
Sample 
Size 
13 informants Total MH hospice 
users: 
4,492 (FY2006) 
5,847 (FY2007) 
6,358 (FY2008) 
9 informants 20 informants 
Data 
Outputs 
Document 
summaries 
Interview transcripts 
MH hospice 
utilization and 
related 
expenditures  
Member 
demographics 
Interview 
transcripts 
Interview 
transcripts 
Analysis Transcript coding 
using Atlas.ti 
Descriptive 
statistics using 
SAS v9.1 
Transcript coding 
using Atlas.ti 
Transcript coding 
using Atlas.ti 
commercial insurance.4
                                               
4 Another much smaller subgroup included MassHealth members with commercial insurance. 
Data from commercial insurers was not available for this study. 
 CHPR accessed the MassHealth hospice claims and enrollment 
data from the Massachusetts Executive Office of Health and Human Services Data 
Warehouse, and linked the two datasets using the Recipient History Number (RHN) for 
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each hospice beneficiary. Frequency statistics with proportions were calculated using 
SAS 9.1. 
Phases 1, 3 and 4 employed qualitative methods. In Phase 1, the study population 
consisted of MA hospice providers, hospice/EOL care provider associations, government 
administrators, and subject matter experts. With MassHealth assistance, CHPR 
generated an initial list of individuals, and then employed snowball sampling techniques 
to identify the final group of 13 key informants representing various hospice 
stakeholders. Semi-structured guides were used in 90-minute interviews conducted in 
person or by telephone. Interview transcripts were inductively coded. Content coding 
and analyses of the CMS Conditions of Participation (CoPs), the MassHealth Hospice 
Manual, and 13 other policy documents were also completed. 
For Phase 3, the study population consisted of surviving family members of MassHealth 
hospice beneficiary decedents. A sample was developed using claims data to first 
identify MH-only hospice decedents from CY2008-2009. This time period was chosen to 
ensure that at least 18 months had lapsed prior to making contact with family members. 
Using the decedents’ case number as a matching criteria, CHPR generated a study 
sample of 64 adult (age 21 years or older) family members of FFS hospice beneficiaries 
who were also enrolled in MassHealth. Following recruitment by mail, a semi-structured 
guide was used to interview subjects by telephone. Transcripts were deductively coded 
and the results analyzed to assess family member experience and satisfaction with the 
hospice benefit. 
In Phase 4, study subjects consisted of key informants from five selected states whose 
Medicaid hospice policies or programs may differ from those in MA. MassHealth 
approved the five states, and CHPR then contacted the state Medicaid office and the 
state Hospice Association to identify participants. A semi-structured interview guide was 
administered via telephone with 20 key informants. Transcripts were coded, and the 
coded text was analyzed to identify differences from, and potential innovations to, the 
MassHealth hospice benefit. 
For this Final Report, CHPR reviewed and analyzed the findings, as detailed in the four 
Hospice study reports, along with relevant literature. The subsequent analysis forms the 
basis for this summary report, including its recommendations regarding policy actions 
and areas for further study. 
4 Synopsis of Study Findings 
Findings from the four phases of the Hospice study are organized around the following 
five themes: 
1) Access, eligibility and election 
2) Service and payment structure 
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3) Utilization and expenditures 
4) Member and family satisfaction 
5) Alternative models for hospice and EOL care in other states 
4.1 Access, Eligibility and Election 
To access hospice services in MA, as well as the five states examined in Phase 4, 
eligible Medicaid members must have documentation of a terminal illness with a life 
expectancy of six months or less, as certified in writing by a physician. Members must 
waive their rights to curative treatment. Informants noted this policy as a barrier to 
hospice access for those patients not ready to “give up” treatment.  
Consistent with results from the literature, this study finds that hospice coverage is not 
available to all Medicaid members. States, such as MA, AZ and OK, restrict eligibility to 
the hospice benefit based on age, disability status, and/or coverage type. MassHealth 
currently excludes members in its Basic, Limited, and Essential coverage plans from the 
FFS hospice benefit. MA hospice providers report they provide free care to Medicaid 
members lacking hospice coverage, based on their indigent status. 
Adult members may postpone hospice election to continue treatment or because they 
are unfamiliar with the range of services the benefit provides. According to key 
informants in Phase 1, LOS in hospice is often too short to implement a comprehensive 
hospice plan of care for patients and families (Lang et al., 2011).  While the average 
LOS for all MassHealth hospice beneficiaries increased during the Phase 2 study period 
(FY 2006-2008), MassHealth hospice users were more likely to have a LOS of one week 
or less.  
4.2 Service and Payment Structure 
The “all-inclusive” service structure of the Medicare hospice benefit is specified in the 
federal Hospice CoPs5
The CoPs dictate that the hospice R&B reimbursement rate must be at least 95% of the 
rate the state would otherwise pay for SNF R&B. This is known as the “95% rule” (Lang 
et al., 2011). States have the authority to pay more than 95% of the SNF rate for hospice 
R&B. Among the states studied, MA, FL and NH reimburse at 95% of the SNF rate, 
, and replicated in the MA Medicaid state plan as well as in the 
five Phase 4 study states. Hospice services are paid on a per diem basis based on four 
levels of care: routine home care; continuous home care; inpatient respite care; and 
general inpatient care. For Medicaid-only hospice beneficiaries, states pay for all 
hospice care, as well as R&B when the member resides in a SNF. For dual eligibles, 
Medicare pays for hospice care while states reimburse only for R&B in SNFs. 
                                               
5 U.S. Department of Health and Human Services, Centers for Medicare & Medicaid 
Services, 42 CFR Part 418 Medicare and Medicaid Programs: Hospice Conditions of 
Participation, Federal Register, Vol. 73, No. 109, June 5, 2008, pgs. 32088-32220 
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while NH and AZ reimburse at 100%. Phase 1 informants reported that in some cases, 
hospice providers in MA have agreements with SNFs to pay 100% of the R&B rate. 
States also differ in regard to hospice R&B reimbursement policies and procedures. 
Generally, hospice providers bill Medicaid for R&B reimbursement which they pass to 
the SNF. MA, as well as FL and NY, use the R&B pass-through system. In MA, hospice 
providers are responsible for obtaining information from SNFs in order to accurately 
calculate the hospice R&B rate. The AZ and NH Medicaid program informants reported, 
however, that their state reimburses hospice R&B directly to SNFs. 
4.3 Utilization and Expenditures 
4.3.1 Utilization 
Both hospice utilization and expenditures grew in MA over the three-year study period, 
driven by change in the number of beneficiaries dually eligible for Medicaid and 
Medicare. The number of dual eligible hospice users grew from 4,117 to 6,051, and their 
average LOS increased from 79 days to 91 days. Further, the proportion of dual eligibles 
within the longest LOS category (more than 6 months) also increased, from 14.3% to 
17.1%. As displayed in Figure 1, for LOS categories longer than one month, the 
proportion of dual eligibles was higher than the proportion of MH-only hospice users.  
Figure 1. Hospice Length of Stay for MH-Only (MHO) and Dual Eligible (DE) 
Hospice Beneficiaries (FY 2006-2008 Average) 
  
Source: (Bhang & Zhang, 2010) 
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MH-only hospice utilization remained steady during FY2006-FY2008, with the number 
virtually constant (619, 621, 622). In each of the three years, the median length of stay 
was 30 days or less (median range, 19 to 30). Less than 10% of all MH-only hospice 
beneficiaries in each year had a LOS longer than 6 months and most (over 50%) were 
served in the community.6
4.3.2 Expenditures 
 Across the study period, the number and proportion of MH-
only members receiving SNF R&B increased from 224 (36.0%) in FY2006 to 256 
(41.4%) in FY2008. 
MassHealth hospice expenditures totaled $58.9 million in FY2006, rose to $87.4 million 
in FY2007, and reached $105.0 million in FY2008, an increase of 78.3% over the three 
years. Expenditures for MH-only hospice users during this period rose from $6.3 million 
to $9.1 million, a 69.2% increase. On average, nearly two-thirds of these expenditures 
covered routine care (53.3%) and general inpatient care (9.2%), and just over one-third 
paid for R&B. Hospice expenditures for dual eligible members increased 82.5% in the 
same period. R&B for dual eligibles residing in SNFs had a great impact on MassHealth 
hospice expenditures, comprising approximately 90% of all MassHealth hospice 
expenditures in each study year (Bhang & Zhang, 2010). Figure 2 below compares total 
hospice expenditures, as well as R&B and hospice care, for MH-only (MHO) and dual 
eligibles (DE) members over the study period. 
Figure 2. MassHealth (MH) Hospice Expenditures for MH-Only (MHO) and Dual 
Eligible (DE) Hospice Beneficiaries, FY 2006-2008 
 
Source: (Bhang & Zhang, 2010) 
                                               
6 MassHealth members who receive hospice services in the community paid for by Medicare or 
commercial insurance are not represented in the Hospice study as data for this population was 
not available. 
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4.4 Member and Family Satisfaction 
All family members interviewed in Phase 3 of the study rated the MassHealth hospice 
benefit as “excellent”. They reported that hospice “more than met” the patients’ needs for 
palliative care and assistance with activities of daily living. Further, hospice supported 
the family members as caregivers. Informants also spoke of the spiritual and emotional 
support which hospice staff provided. This often included helping the families accept and 
prepare for their loved one’s death. One respondent noted the importance of having 
hospice staff available who could speak to family members in their primary language. 
4.5 Alternative Models for Hospice and End-of-Life Care in Other 
States 
The five states in Phase 4 of the Hospice study have implemented care models and 
policies to improve both the efficiency and breadth of EOL care. While none currently 
offer an EOL care benefit for adult Medicaid members other than hospice, they will 
authorize FFS payment for services, in addition to treatment, that are related to a 
member’s terminal illness, regardless of hospice eligibility. Such services include home 
health, personal care attendants (PCAs), private duty nursing, durable medical 
equipment, and medication. 
States have the flexibility to develop Home and Community-Based Services (HCBS) 
waivers for Medicaid members who are elderly or disabled and who would otherwise be 
institutionalized. AZ and OK include FFS hospice in their HCBS waiver programs for 
adult members needing long term care. FL and NY each use waivers to provide 
palliative care services to Medicaid children with chronic or life-limiting conditions.7
MA and all the study states, except FL, have implemented Section 2302 of the federal 
Affordable Care Act, Concurrent Care for Children, which allows coverage of curative 
treatment for Medicaid members younger than 21 years of age who elect the hospice 
benefit.
 
8 NY enacted laws9
Unlike MA, AZ does not use the pass–through payment system for SNF reimbursement. 
Rather, it directly pays SNFs 100% of their R&B rate for FFS hospice beneficiaries. NH 
also reimburses at 100%, a policy implemented to promote positive relationships 
 aimed at improving all patients’ knowledge of and access to 
palliative care, and is currently considering Medicaid redesign to both implement the 
law’s provisions through its Medicaid program and to expand hospice eligibility (Lang & 
Posner, 2012). 
                                               
7 The Massachusetts Pediatric Palliative Care Program provides similar services; however, it is 
funded as a state Department of Public Health program, separate from MassHealth. 
8 PL 111-148 Patient Protection and Affordable Care Act, Title II, Sub. D, §2302, “Concurrent 
Care for Children” (124 STAT. 293) 3/23/10. 
9 The Palliative Care Information Act (PCIA), eff. 2/1/2011, and The Palliative Care Access Act, 
eff. 9/27/2011 (PCAA).  
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between hospice providers and SNFs and avoid the tensions MA providers reported in 
Phase 1. 
5 Study Limitations 
Data access and sampling issues limit the study’s results and generalizability. For Phase 
2, only MassHealth claims data were available. The availability of claims data for the four 
levels of hospice care was thus limited to the MH-only population. Without Medicare 
claims data, CHPR was not able to fully examine hospice care expenditures for dual 
eligibles. In addition, the available data was not sufficient to construct a valid comparison 
group of terminally ill MassHealth beneficiaries who did not elect the hospice benefit or 
were not eligible. 
In Phase 3, MassHealth preferred not to rely on family member satisfaction surveys 
routinely used by hospice providers, nor to request family member contact information 
from providers as a means of identifying study participants. While this sample selection 
approach avoided potential bias associated with providers supplying data or selecting 
respondents, it limited the sample size. Thus, the results are not generalizable to the 
population of MassHealth hospice beneficiaries and their families. Although interviewing 
family members of hospice decedents who died 20-35 months prior to data collection 
was done purposefully to respect their bereavement, it may have introduced recall bias. 
Finally, the experiences and opinions of family members who volunteered to participate 
in interviews may have differed from those who did not. 
6 Discussion 
Many studies have found that hospice provides high quality care that is well received by 
chronically or terminally ill patients and their families. This finding was corroborated by 
the family members of hospice decedents who participated in Phase 3 of the Hospice 
study. Thus, delays in patients’ hospice election and restrictions on eligibility for the 
benefit can limit its positive impact for terminally ill MassHealth members. 
The R&B pass-through reimbursement system, where hospice providers serve as billing 
intermediaries between MassHealth and SNFs, presents a number of challenges. 
Payments are delayed when hospices must obtain data from SNFs to accurately 
calculate the hospice R&B rate, submit claims to MassHealth, and pass the R&B 
reimbursement to SNFs. As reported by Phase 1 informants, SNFs have been known to 
charge hospice providers 100% of the R&B rate, since MassHealth only pays 95%. 
These scenarios can create tension between SNFs and providers which may jeopardize: 
1) access to hospice for MassHealth members residing in SNFs that are not inclined to 
accept the 95% hospice R&B rate; and 2) the financial viability of hospice providers 
when they are expected to subsidize R&B for MassHealth hospice beneficiaries in SNFs. 
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Some states do not rely on the pass-through system, nor do they follow the 95% rule. 
For example, AZ and NH reimburse SNFs directly for 100% of the R&B cost for Medicaid 
residents who elect hospice. Informants from NH stated that the state’s policy to pay the 
full SNF R&B rate was established purposefully to foster positive relationships between 
SNFs and hospice providers. 
MassHealth, along with other Medicaid programs, has experienced significant growth in 
hospice R&B expenditures for dual eligibles, which accounted for 90% of its annual FFS 
hospice budget in FY 2006-2008. However, MassHealth pays R&B for its beneficiaries 
who reside in SNFs regardless of their hospice use. Pass-through merely shifts the 
attribution of R&B costs from SNFs to hospice, which may lead to misperceptions about 
the cost of Medicaid hospice care. 
Despite federal and state legislative action, and innovative care models and payment 
policies for terminally ill Medicaid members, the states in the Hospice study do not offer 
a Medicaid state plan benefit providing palliative and hospice care, along with curative 
treatment, for all beneficiaries with chronic/terminal illness, regardless of their age or life 
expectancy. Further examination of MassHealth expenditures, e.g. curative treatment or 
acute care episodes, for terminally ill MH-only members who lack access to or forego the 
hospice benefit as compared to claims for MH-only hospice users, could inform the 
feasibility of expansion of the hospice benefit.10
7 Recommendations 
   
Based on the Hospice study, the following recommendations suggest opportunities for 
MassHealth to improve EOL care in a cost efficient manner for all members with a 
terminal illness. 
7.1 Examine MassHealth Hospice Reimbursement  
• If deemed legal under federal regulations, consider eliminating the pass-
through system by reimbursing R&B for MassHealth hospice beneficiaries 
directly to SNFs. Elimination of the R&B payment pass-through system, as 
exemplified in AZ and NH, and advocated by hospice providers in MA, could 
streamline hospice billing procedures and speed up the reimbursement 
process. It could also promote more positive relationships between hospices 
and SNFs. In turn, this policy change could foster access to hospice by 
MassHealth-only members already residing in SNFs.  
• Consider reimbursing hospice R&B at 100% of the SNF rate. Once a 
MassHealth SNF resident elects hospice, MassHealth pays 95% of what it had 
                                               
10 When Florida considered eliminating its Medicaid hospice benefit in 2008, an independent 
evaluation conducted by the Moran Company showed such action would “likely result in 
increased spending for mandatory services”. 
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paid prior to hospice election. However, in cases where SNFs expect R&B 
reimbursement to continue at 100%, hospice providers either make up the 5% 
difference or decline to provide hospice services. Access to hospice care may 
thus be limited for MassHealth members in these SNFs.  
7.2 Consider Opportunities for Further Study  
• Given preliminary results showing differences in LOS and cost between MH-
only and dually eligible hospice beneficiaries, further analyses of their 
characteristics (e.g., patient diagnoses, patient demographics); hospice 
eligibility, referral and election; care settings; and costs related to the terminal 
illness are warranted.  
• Conduct a case-control study of FFS claims and caregiver experience for 
MassHealth members in Limited, Basic and Essential plans and MH-only 
hospice beneficiaries who died in the past three years to compare 
expenditures and care quality for these populations during the last six months 
of life. Results could determine potential savings for MassHealth and 
opportunities to improve EOL care, and thus advise the feasibility of 
expanding access to the hospice benefit. 
• Analyze FFS claims related to treatment and palliative care services (e.g., 
medications, home health, PCA, medical equipment, physician services, 
consultations), as well as hospitalizations and/or emergency room visits, to 
determine utilization and expenditures for these services by terminally ill MH-
only beneficiaries not enrolled in hospice.  
• Examine palliative care and hospice offered through the MassHealth 
managed care plans. Analyses can examine the current utilization of hospice 
by MassHealth managed care plan members, including service delivery and 
payment structure.    
• Conducted simultaneously with the analyses of claims data, the results from 
additional qualitative studies could advise how health care providers and 
skilled nursing facility officials, as well as hospice providers, view EOL care 
options for MassHealth hospice beneficiaries, including those enrolled in 
managed care plans. 
8 Conclusion 
Studies, including the MassHealth Hospice Program: Overview and Analysis, suggest 
that hospice can improve quality of life and meet the needs of terminally ill patients and 
their families. Family members of MassHealth hospice beneficiaries were very satisfied 
with the benefit. However, not all MassHealth coverage plans include hospice. Lack of  
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access to the hospice benefit, or delay in referral and election of hospice, may impact 
MassHealth members’ end-of-life care. This may be countered by offering a benefit with 
a range of services, designed to meet the needs of terminally ill members and their 
families, as they transition from diagnosis through the end of life. 
Room and board charges for dual eligibles in skilled nursing facilities comprised 90% of 
MassHealth hospice expenditures in SFY2008. The remaining 10% covered the array of 
hospice care services. By acknowledging this budgetary imbalance, and considering 
other state and national models, MassHealth can promote quality and cost-effective care 
options for all its members throughout the progression of a serious chronic and terminal 
illness. 
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